高脂血症应用阿托伐他汀钙片与血脂康治疗的临床分析

高脂血症应用阿托伐他汀钙片与血脂康治疗的临床分析

摘要：目的：观察高脂血症患者在应用阿托伐他汀钙片和血脂康治疗后的疗效和安全性。方法：选择2019年1月至2020年12月我院收治的高脂血症患者120例，随机分成两组，一组应用阿托伐他汀钙片治疗，另一组应用血脂康治疗，治疗时间均为6个月。分别在治疗前和治疗后3个月进行血脂水平的检测，同时观察治疗期间的不良反应。结果：两组患者治疗后的甘油三酯、总胆固醇、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇水平均明显低于治疗前（P<0.05），其中阿托伐他汀钙片组患者降低程度更显著（P<0.01）。治疗期间两组患者均未出现严重不良反应，轻微不适症状率相似。结论：阿托伐他汀钙片和血脂康均可有效降低高脂血症患者的血脂水平，且两种药物的安全性相似，但阿托伐他汀钙片治疗效果更优。

关键字：高脂血症、阿托伐他汀钙片、血脂康、疗效、安全性

Abstract: Objective: To observe the efficacy and safety of atorvastatin calcium tablets and xuezhikang in the treatment of patients with hyperlipidemia. Methods: 120 patients with hyperlipidemia admitted to our hospital from January 2019 to December 2020 were randomly divided into two groups, one group was treated with atorvastatin calcium tablets, and the other group was treated with xuezhikang. The treatment time was 6 months. Blood lipid levels were detected before and 3 months after treatment, and adverse reactions during treatment were observed. Results: The levels of triglycerides, total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in both groups of patients after treatment were significantly lower than those before treatment (P <0.05). Among them, the decrease in the atorvastatin calcium group was more significant (P <0.01). During the treatment period, no serious adverse reactions occurred in both groups of patients, and the incidence of mild discomfort symptoms was similar. Conclusion: Atorvastatin calcium tablets and xuezhikang can effectively reduce the blood lipid levels of patients with hyperlipidemia, and the safety of the two drugs is similar, but the therapeutic effect of atorvastatin calcium tablets is better.

Keywords: hyperlipidemia, atorvastatin calcium tablets, xuezhikang, efficacy, safety